• 한국융합학회논문지
• /
• 제7권4호
• /
• pp.39-44
• /
• 2016

최근 IT시대인 만큼 IT기술의 눈부신 발전으로 인해 사물 대 사물, 사물 대 사람, 사람 대 사람 간의 정보 전달 기술이 활발해지고 있다. 정보 전달 기술이 활발해 지고 있는 만큼 IoT는 우리 일상생활에 밀접하게 다가와 언제 어디에서나 흔하게 볼 수 있을 만큼 우리 일상생활의 한 부분을 차지하고 있다. IoT 환경에서는 주로 웹기반 프로토콜인 CoAP 프로토콜을 사용한다. CoAP 프로토콜은 전송 속도가 낮고 손실이 큰 네트워크에서 주로 사용되기 때문에 IoT 환경에서 주로 사용된다. 그러나 IoT는 보안적으로 취약하다는 단점이 있다. 만약, IoT 환경에서 보안에 노출 될 경우 개인정보 또는 기업의 기밀 정보 등이 유출 될 가능성이 있다. 공격자가 IoT 환경에서 대상 디바이스를 감염 시킨 후 감염된 디바이스가 공공장소에서 흔히 사용되는 무선인터넷에 접속 했을 시 장악된 디바이스는 내부망에 있는 디바이스들에게 arp spoofing을 보낸다. 그 후 내부망 패킷의 흐름을 장악한 후에 내부망에 있는 디바이스들이 보내는 패킷을 감염된 디바이스가 받아 지정된 해커의 서버에 보낸다. 본 논문에서는 이에 관한 공격 방법과 대응방안을 제안한다.

• Journal of Dental Anesthesia and Pain Medicine
• /
• 제21권5호
• /
• pp.413-429
• /
• 2021

Background: Migraine headaches are the second leading cause of disability worldwide and are responsible for significant morbidity, reduction in the quality of life, and loss of productivity on a global scale. The purpose of this systematic review and meta-analysis was to evaluate the efficacy of ketamine on migraines and other primary headache disorders compared to placebo and other active interventions, such as midazolam, metoclopramide/diphenhydramine, and prochlorperazine/diphenhydramine. Methods: An electronic search of databases published up to February 2021, including Medline via PubMed, EMBASE, Web of Science, and Cochrane Library, a hand search of the bibliographies of the included studies, as well as literature and systematic reviews found through the search was conducted to identify randomized controlled trials (RCTs) investigating ketamine in the treatment of migraine/headache disorders compared to the placebo. The authors assessed the risk of bias according to the Cochrane Handbook guidelines. Results: The initial search strategy yielded 398 unduplicated references, which were independently assessed by three review authors. After evaluation, this number was reduced to five RCTs (two unclear risk of bias and three high risk of bias). The total number of patients in all the studies was 193. Due to the high risk of bias, small sample size, heterogeneity of the outcomes reported, and heterogeneity of the comparison groups, the quality of the evidence was very low. One RCT reported that intranasal ketamine was superior to intranasal midazolam in improving the aura attack severity, but not duration, while another reported that intranasal ketamine was not superior to metoclopramide and diphenhydramine in reducing the headache severity. In one trial, subcutaneous ketamine was superior to saline in migraine severity reduction; however, intravenous (I.V.) ketamine was inferior to I.V. prochlorperazine and diphenhydramine in another study. Conclusion: Further double-blind controlled studies are needed to assess the efficacy of ketamine in treating acute and chronic refractory migraines and other primary headaches using intranasal and subcutaneous routes. These studies should include a long-term follow-up and different ketamine dosages in diagnosed patients following international standards for diagnosing headache/migraine.